leisure time -WSS

leisure time

author：fashion 2025-09-27 12:34:16 - browse：4

Have you ever seen a mouse with a set of muscles more appropriate for a bodybuilder or comic book superhero?

Well, 25 years ago, researchers at Johns Hopkins University made it happen. By silencing a gene responsible for producing a protein called myostatin, they directed tiny mouse bodies to grow double the amount of lean muscle they would normally, leading to mice with bulky arms, defined pectorals, and an overall more substantial body mass. They were dubbed “mighty mice.”

Now, biotech startups are hoping to use those findings to create what they believe will be better weight loss medications. In the last several months, multiple companies have disclosed they are testing drugs that preserve or grow muscle while reducing fat, as shown in the updated STAT Obesity Drug Tracker. They hope that their drugs, possibly when used in conjunction with existing obesity treatments, will result in healthier weight loss.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

WSS

What we’ve learned from the Aduhelm mess

Vaccine advisory panel ACIP left half staffed by HHS

DeepMind touts AlphaFold's new skills as protein folding AI models face off

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Biden report: The neurospychology of memory and aging

Medicare Advantage proposed rates disappoint insurers

Wikipedia

leisure time

knowledge

Supreme Court strikes down use of affirmative action

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

DIEP, the 'gold standard' of breast reconstruction, is under threat

Robert F. Kennedy is pitching centrism on health, even on abortion

Alkermes shareholders re

Private equity deals in Medicare Advantage declines

23andMe had bad news about my health. I wish a person had delivered it

To avoid data mishandling cases, universities eye AI and other tools

In age of alternative facts, a scholarly course on calling out crap

The Readout: Gilead, Bernie Sanders, and other pharma news

explore

Medical mystery: When a cough is not just a cough

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Sarepta Duchenne therapy fails to meet primary endpoint in trial

Industry veterans launch new biotech VC with $310M

explore

hotspot

explore

knowledge